| P/E (FY) | — | Sales (TTM) | $217.8M |
| Earnings (TTM) | -$33.6M | ROE | −8.21% |
| Net Margin | −18.08% | ROIC | −22.74% |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | −16.54% |
| Market Cap | $5.31B | Trading Days | 5293 |
| 52W High | 20.90 |
| 52W Low | 13.12 |
| % Off High | −33.25% |
| YTD | −0.07% | 1Y | −6.94% |
| 3Y | −41.39% | 5Y | −83.70% |
| 10Y | −70.82% | Since incept. (ann.) | −13.07% |
Product 86% · Licensing And Royalty 14%
| Ann. Volatility (1Y) | 45.16% | Ann. Volatility (3Y) | 65.50% |
| Sharpe (1Y) | 0.06 | Sharpe (3Y) | 0.08 |
| Max Drawdown (1Y) | −33.33% | Max Drawdown (3Y) | −70.36% |
| Beta (3Y, vs SPY) | 0.94 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| TVTX | Travere Therapeutics, Inc. | $5.20B | — |
| ORKA | Oruka Therapeutics, Inc. | $5.46B | — |
| DNTH | Dianthus Therapeutics, Inc. /DE/ | $5.55B | — |
| INDV | Indivior Pharmaceuticals, Inc. | $5.00B | 25.0 |
| ERAS | Erasca, Inc. | $5.65B | — |
| LGND | LIGAND PHARMACEUTICALS INC | $5.94B | 48.3 |
| AMRX | Amneal Pharmaceuticals, Inc. | $5.98B | 85.3 |
| MANE | Veradermics, Inc | $4.66B | — |
| KNSA | Kiniksa Pharmaceuticals International, plc | $6.27B | 105.9 |
| XENE | Xenon Pharmaceuticals Inc. | $6.28B | — |
| ACAD | ACADIA PHARMACEUTICALS INC | $4.45B |
| 11.3 |
| COGT | Cogent Biosciences, Inc. | $6.48B | — |
